Teligent Weighs Sales Of Non-Core Assets
Seeking Funds To Unlock Potential Of New Injectables Facility
US topicals, ophthalmics and injectables generics player Teligent has asked an investment bank to help it explore selling off non-core assets. The New Jersey-based firm wants funds to help capitalize on its newly built injectables facility.
You may also be interested in...
Teligent CEO Jason Grenfell-Gardner has stepped down with immediate effect, while Centrient CEO Karl Rotthier is preparing to leave the role in March. Both firms have announced details of their replacements. Meanwhile, Stada has appointed a new chief financial officer.
US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.